Kannalife Inc. is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from their proprietary cannabinoid product platform in a broad range of disease areas. In 2012, the company was awarded an exclusive license for the commercialization of U.S. Patent #6630507 for the treatment of hepatic encephalopathy (HE) and again in 2014 for the treatment of chronic traumatic encephalopathy (CTE). The patent license, "Cannabinoids as Antioxidants and Neuroprotectants," allowed Kannalife to research the effects of cannabidiol (CBD) around HE and CTE and ultimately lead to the Company's discovery of its own family of proprietary CBD-derived molecules. One such molecule, KLS-13019, has been found to be 50-times more potent and more than 400-times safer than CBD, and now stands as the Company's lead target drug candidate.

KLS-13019, is part of an intellectual property estate of new chemical entities (NCEs) underlying U.S. Patent #9611213 titled “Functionalized 1,3 Benzene-diols and their Method of Use for the Treatment of Hepatic Encephalopathy” and U.S. Patent #10004722 titled “Method for Treating Hepatic Encephalopathy or a Disease Associated with Free Radical Mediate Stress and Oxidative Stress with Novel Functionalized 1,3 Benzene-diols.”

In 2017, Kannalife was also awarded a grant from the National Institutes of Health (NIH) to research chemotherapy-induced peripheral neuropathy (CIPN) and drug dependency. Here, in extensive pre-clinical evaluation with Temple University, KLS-13019 has outperformed CBD and may also be a suitable replacement for opiates currently in use for this indication. Kannalife continues to conduct its research and development efforts at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA.